|Day's Range||0.0800 - 0.1500|
Bernard Tyson, Kaiser Permanente CEO & Steven Van Kuiken, McKinsey Senior Partner at Yahoo Finance All Markets Summit: Generational Opportunities.
How Bernard Tyson, CEO of Kaiser Permanente, says his California-based insurer is dealing with the power outages in the state.
Bernard Tyson, Kaiser Permanente CEO, and Steven Van Kuiken, McKinsey Senior Partner, discuss how government can improve the health care system in the US.
In a conversation with Yahoo Finance, Bernard Tyson, Kaiser Permanente CEO, and Steven Van Kuiken, McKinsey Senior Partner, talk about how innovation is rapidly improving health outcomes and making the health care system more efficient.
In a conversation with Yahoo Finance, Bernard Tyson, Kaiser Permanente CEO, and Steven Van Kuiken, McKinsey Senior Partner, talk about how millennials are not going to accept the way the health care system works today.
In a conversation with Yahoo Finance, Bernard Tyson, Kaiser Permanente CEO, and Steven Van Kuiken, McKinsey Senior Partner, discuss how the cost of health care for consumers have risen faster than inflation while innovation and technology have made the cost of care more expensive.
Bernard Tyson, Kaiser Permanente CEO, says we shouldn't just focus on the cost of health insurance for consumers, but also on the inefficiencies of care and inconsistencies in practice.
President Trump signed an executive order that his administration says will "protect" Americans from “Medicare for all" campaign proposals pushed by democrats. Ivan Feinseth, Tigress Financial Partners CIO, joins Yahoo Finance's Akiko Fujita.
Geopolitical tensions continue to weigh on investors as events like the September 14th attack on Saudi Arabia’s oil production test overall sentiment. Brandon Pizzurro, GuideStone Capital Management Portfolio Manager, joins Yahoo Finance's On The Move to discuss.
Victoria Fernandez, chief market strategist at Crossmark Global Investments, and Scott Clemons, chief investment strategist at Brown Brothers Harriman, join Yahoo Finance's Brian Sozzi, Alexis Christoforous, and Jared Blikre to discuss what's moving markets on Tuesday, Sept. 24. The panel tackles the housing market, Sen. Bernie Sanders' new wealth tax proposal, and more.
Shares of Johnson & Johnson suffers another blow Friday related to product safety, as the consumer products giant’s recall of some baby powder, after tests reveal traces of asbestos.
Shares of McKesson Corp. rallied 5.7% in midday trading Wednesday, enough to pace all of its larger-capitalization health care peers, after The Wall Street Journal reported that the drug distributor, and two others, were in talks to pay $18 billion to settle all litigation brought by state and local governments blaming the companies for fueling the opioid crisis. Of the other two drug distributors, shares of AmerisourceBergen Corp. climbed 4.7% and Cardinal Health Inc. hiked up 3.7%. Shares of Johnson & Johnson rose 2.4% after the WSJ report out late Tuesday, citing people familiar with the situation, said the company was also involved in the discussions to contribute additional money. The four companies' stocks topped the list of gainers in the SPDR Health Care Select Sector ETF , which inched up 0.1%, while the S&P 500 slipped 0.2%.
Shares of Abbott Laboratories fell 2.7% in premarket trading Wednesday, after medical device, diagnostics and drug maker reported a third-quarter profit that was in line with expectations, while sales came up a bit shy. Net income rose to $960 million, or 53 cents a share, from $563 million, or 32 cents a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share grew to 84 cents from 75 cents, matching the FactSet consensus of 84 cents. Sales increased 5.5% to $8.08 billion, below the FactSet consensus of $8.11 billion. Within Abbott's business segments, revenue for medical devices was slightly above expectations, while nutrition, diagnostics and established pharmaceuticals was slightly below. Looking ahead, Abbott expects fourth-quarter adjusted EPS of 94 cents to 96 cents, surrounding the FactSet consensus of 95 cents, and narrowed its 2019 guidance range to $3.23 to $3.25 from $3.21 to $3.27. The stock has gained 13.3% year to date through Tuesday, while the SPDR Health Care Select Sector ETF has advanced 5.8% and the S&P 500 has climbed 19.5%.
Healthcare stocks and sector-related exchange traded funds found support from a strong start to the earnings season after UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) provided a much ...
While markets have had a choppy week, 2019 has revealed some outstanding performers in certain underrated sectors. Technology and healthcare have been solid spaces to invest in, despite how the headlines might appear.
While markets have had a choppy week, 2019 has revealed some outstanding performers in certain underrated sectors. Technology and healthcare have been solid spaces to invest in, despite how the headlines might appear. “With respect to tech and healthcare, I think it’s pretty easy to say that both sectors are trading devoid of fundamentals.
The Health Care Select Sector SPDR (NYSE: XLV), the largest health care exchange traded fund by assets, is up a piddly 2.58% year to date. Said differently, the SPDR S&P 500 ETF (NYSE: SPY) is beating XLV by a margin of about 7-to-1. Whether it has been the Medicare For All debate or the push for lower drug prices, XLV and rival health care ETFs have been hammered on multiple political fronts this year.
Healthcare and biotechnology-related ETFs are taking a blow as drug-pricing reforms weigh on the sector outlook. The Health Care Select Sector SPDR ETF (XLV) fell another 0.6% and the iShares Nasdaq Biotechnology ETF (IBB) declined 2.0% in back-to-back selling on Thursday. The biotech segment and broader healthcare sector have underperformed the broader market as investors exited positions in response to growing discourse over policy proposals aimed at reducing drug prices in Washington, Bloomberg reports.